Company Overview of Boston Therapeutics, Inc.
Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in ve...
1750 Elm Street
Manchester, NH 03104
Founded in 2009
Key Executives for Boston Therapeutics, Inc.
Total Annual Compensation: $71.7K
Chief Financial Officer
Total Annual Compensation: $68.1K
Compensation as of Fiscal Year 2013.
Boston Therapeutics, Inc. Key Developments
Boston Therapeutics, Inc. Appoints Benjamin Rivnay as Chief Scientist
Jul 9 14
Boston Therapeutics, Inc. has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the company's science and technology. He will serve as the primary liaison to the company's Medical Advisory Board and report to Rom E. Eliaz, Ph.D., chairman of the board of directors Scientific Advisory Committee. Dr. Rivnay is a seasoned director of technology and research activities within the biotechnology industry. Most recently, he was Director of Research and Development at Formatech Inc.
Kenneth A. Tassey, Jr. Resigns as President and Director of Boston Therapeutics, Inc
Jul 3 14
Effective as of June 30, 2014, Kenneth A. Tassey, Jr. resigned as President and a director of Boston Therapeutics, Inc. Mr. Tassey's resignation was not the result of any disagreements with the company regarding its operations, policies, or practices.
Boston Therapeutics Initiates Phase IIb Study to Assess the Efficacy and Safety of SUGARDOWN(R) for Type 2 Diabetes
May 29 14
Boston Therapeutics, Inc. has initiated a Phase IIb clinical study to assess the efficacy and safety of SUGARDOWN(R) in 24 patients with Type 2 diabetes taking metformin. The study, SD-002, is being conducted by Accumed Research Associates in Garden City, NY under the direction of Principal Investigator Mitchell D. Efros, MD, FACS. SUGARDOWN(R) is Boston Therapeutics' (BTI) currently marketed dietary supplement that is intended to support healthy blood sugar. Previous clinical studies have indicated that SUGARDOWN(R) can maintain healthy glucose levels even after meals when sugar tends to spike. The five-week, randomized, double-blind Phase IIb study is designed to assess the safety and efficacy of SUGARDOWN(R) in two different doses versus placebo on serum glucose levels after meals in 24 subjects with Type 2 diabetes treated with metformin alone. The primary endpoint of the study is postprandial serum glucose area under the curve; secondary endpoints are peak postprandial serum glucose, time to peak postprandial serum glucose, and peak blood serum excursion at two hours from baseline.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|